14th Dec 2015 15:03
CANBERA (dpa-AFX) - An Australian court has ordered the Nurofen "specific pain" range of products off shelves after finding that its manufacturer Reckitt Benckiser (Australia) misled the consumers by representing that its products were each formulated to treat a specific type of pain, when the products are identical.
The Nurofen Specific Pain product range consists of Nurofen Back Pain, Nurofen Period Pain, Nurofen Migraine Pain and Nurofen Tension Headache.
In proceedings commenced by the Australian Competition and Consumer Commission, the Federal Court Monday said that it has found that Reckitt Benckiser made misleading representations on the packaging of each Nurofen Specific Pain product, and on its website that each product was formulated to treat a particular type of pain; and solely or specifically treated a particular type of pain.
In fact, each product contains the same active ingredient, ibuprofen lysine 342mg, and is no more effective at treating the type of pain described on its packaging than any of the other Nurofen Specific Pain products.
Reckitt Benckiser admitted that it had engaged in the contravening conduct and consented to the orders made by the Court.
Copyright RTT News/dpa-AFX
Related Shares:
RB..L